加载中
NASDAQHealthcareBiotechnology
最新数据
US$7.35
−US$0.12 · -1.61%
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
常规交易时段
US$7.35
−US$0.12 · -1.61%
盘中时间采用ET。市场数据可能有所延迟。
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
日内区间
当前US$7.35
52周区间
当前US$7.35
盘中时间采用ET。市场数据可能有所延迟。
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
日内区间
当前US$7.35
52周区间
当前US$7.35
| 项目（USD） | 2025财年 |
|---|---|
| 销货成本 | 2417.6万 USD |
| 毛利 | −2417.6万 USD |
| 研究与开发 | 2.5亿 USD |
| 销售、一般及管理费用 | 8862.7万 USD |
| 营业费用 | 3.15亿 USD |
| 利息收入 | 1556.6万 USD |
| 利息支出 | 83.7万 USD |
| 折旧和摊销 | 2417.6万 USD |
| 营业利润 | −3.39亿 USD |
| 净利润 | −3.24亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$5.00
下跌空间 31.97%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI690.48万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM610.17万0.01%787.4亿 USD0.19%US$278.1-0.30%
Vanguard Extended Market ETFVXF252.19万0.00%954亿 USD0.05%US$234.07-0.40%
iShares Russell 2000 Growth ETFIWO150.59万0.01%139.17亿 USD0.24%US$354.95-0.51%
Vanguard Russell 2000 ETFVTWO130.73万0.01%180亿 USD0.06%US$112.35-0.28%
Schwab U.S. Small-Cap ETFSCHA114.77万0.01%218.24亿 USD0.03%US$32.70-0.27%
iShares Micro-Cap ETFIWC74.85万0.06%13.17亿 USD0.60%US$182.19-0.44%
ALPS Medical Breakthroughs ETFSBIO51.01万0.27%1.91亿 USD0.50%US$54.78-0.47%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
